Apogen Biotechnologies, a US-based oncological therapy spinout of University of Minnesota, boosted its series A round to $11m yesterday with a $4m extension from investors including pharmaceutical firm Merck Group.
Merck contributed to the capital through its corporate venturing subsidiary M Ventures, and was joined by unnamed, existing investors.
Apogen previously raised an initial $7m tranche in 2016 from WRF Capital, the investment arm of commercialisation firm Washington Research Foundation, Arch Venture Partners and Accelerator Life Science…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?